Oral Hsp90 inhibitor, SNX-5422, attenuates SARS-CoV-2 replication and dampens inflammation in airway cells.
R. Goswami, V. S. Russell, J. J. Tu, P. Hughes, F. Kelly, S. N. Langel, J. Steppe, S. M. Palmer, T. Haystead, M. Blasi, S. R. Permar
This study shows that the Hsp90 inhibitor SNX-5422 reduces SARS-CoV-2 replication and inflammation in airway cells, suggesting its potential as an early therapeutic.
bioRxiv · Feb 23, 2021Microbiology